Big biotech, Big pharma, Biotech, Partnering

Medimmune licenses Omnis’ immuno-oncology program

Posted on 13 January 2015

Tags: , ,

MedImmune has entered into a licensing agreement with Omnis Pharmaceuticals.

This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV).

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.

Oncolytic viruses are designed to target tumour cells with the killing potency of viruses.

VSV is among a group of naturally occurring viruses that can be engineered to selectively infect tumour cells and destroy them without harming healthy cells.

These oncolytic viruses represent a potentially powerful new tool in the fight against cancer and may be synergistic with various immunotherapies currently being developed by MedImmune.

MedImmune has the license to develop and, if successful, to commercialise Omnis’s lead oncolytic virus programme.

Clinical development of the virus will be accelerated with the objective of rapidly progressing to combination studies with MedImmune’s immunotherapy molecules.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Print Friendly, PDF & Email

Leave a Reply